NCT07415837 Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
| NCT ID | NCT07415837 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Duchenne / Becker Muscular Dystrophy |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2026-02-11 |
| Primary Completion | 2029-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 104 participants in total. It began in 2026-02-11 with a primary completion date of 2029-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases. MicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease. The main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities: 1. Patients with Duchenne or Becker muscular dystrophy (DMD/DMB). 2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease). 3. Patients with congenital myopathies. 4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.
Eligibility Criteria
Inclusion Criteria: * Age: Participants must be older than 2 years of age * Consent: Participants (or their legal guardians) must provide free and informed consent,. For children, the consent is oral for those under 6 years old and written for those over 6,. * Social Security: Every participant must be affiliated with the French social security system. * Participants must have a diagnosed neuromuscular pathology : the eligible pathologies are Myotonic Dystrophy Type 1 (DM1 or Steinert's disease), Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (DMB), or congenital myopathies or are healthy participants. Exclusion Criteria: * Refusal to participate expressed by the subject or their parental authority. * Engaging in intense and unusual physical effort within 10 days before the blood draw. * Current use of any treatment with systemic, muscular, or cardiac effects that could interfere with the study's biological results. * Subjects or their legal guardians who are under tutelage, curatorship, deprived of liberty, or under judicial protection. * Women who are pregnant or breastfeeding. * The presence of an additional pathology that, in the judgment of the clinician, could interfere with the biological findings
Contact & Investigator
Catherine Sarret, MD, PhD, Prof
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT07415837 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, studying Duchenne / Becker Muscular Dystrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07415837 currently recruiting?
Yes, NCT07415837 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT07415837 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France.
Who is sponsoring the NCT07415837 clinical trial?
NCT07415837 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Catherine Sarret, MD, PhD, Prof at University Hospital, Clermont-Ferrand. The trial plans to enroll 104 participants.